

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 21
 ICB commissioned 5
 Non-ICB commissioned 10
 Not applicable 6
 ICB commissioned and approved 1 (20%)
 Average days to compliance 48

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA963]	Recommended	03/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [TA964]	Recommended	10/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) [TA966]	Terminated appraisal	24/04/2024	TA					N/A	Terminated appraisal
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA968]	Terminated appraisal	25/04/2024	TA					N/A	Terminated appraisal
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) [TA969]	Terminated appraisal	30/04/2024	TA					N/A	Terminated appraisal
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over [TA967]	Recommended	01/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [TA971]	Recommended	08/05/2024	TA (EAMS)	07/06/2024	ICB	25/06/2024	48	These technologies are commissioned by integrated care boards. Providers are NHS hospital trusts	Red statement for remdesivir. Black RAG for tixagevimab plus cilgavimab
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [TA970]	Recommended	08/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under [TA975]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma [TA974]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Atogepant for preventing migraine [TA973]	Recommended	15/05/2024	TA	13/08/2024	ICB			This technology is commissioned by ICBs. Providers are secondary care acute hospital trusts (headache clinic) or primary care GP.	APG statement
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia [TA298]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration [TA155]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion [TA283]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Cladribine for treating relapsing–remitting multiple sclerosis [TA616]	Recommended	21/05/2024	TA (Update)		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis [TA312]	Recommended	21/05/2024	TA (Update)		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis [TA127]	Recommended	21/05/2024	TA (Update)		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) [TA972]	Terminated appraisal	22/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) [TA978]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [TA977]	Recommended	29/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA976]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a	Terminated appraisal